EZH2 expression is restricted to malignant salivary gland tumors.

IF 2.6 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Applied Oral Science Pub Date : 2025-06-09 eCollection Date: 2025-01-01 DOI:10.1590/1678-7757-2025-0123

Dusit Bumalee, Prow Janjarussakul, Jintana Pankam, Tawepong Arayapisit, Nakarin Kitkumthorn, Teerat Chanamorn, Amanda Li Yin Goh, Puangwan Lapthanasupkul

{"title":"EZH2 expression is restricted to malignant salivary gland tumors.","authors":"Dusit Bumalee, Prow Janjarussakul, Jintana Pankam, Tawepong Arayapisit, Nakarin Kitkumthorn, Teerat Chanamorn, Amanda Li Yin Goh, Puangwan Lapthanasupkul","doi":"10.1590/1678-7757-2025-0123","DOIUrl":null,"url":null,"abstract":"Background: Enhancer of zeste homolog 2 (EZH2) configures a histone methyl transferase enzyme that mediates the epigenetic silencing of target genes. Its overexpression has been related to tumor proliferation, metastasis, and poor prognoses. However, the study of this protein in salivary gland tumors (SGTs) remains limited.Objective: This study aimed to investigate EZH2 expression in common intra-oral SGTs, including pleomorphic adenoma (PA), mucoepidermoid carcinoma (MEC), and adenoid cystic carcinoma (ACC).Methodology: A total of 48 formalin-fixed paraffin-embedded tissue samples were analyzed, including 17 PA, 21 MEC, and 10 ACC cases. Immunohistochemical staining was performed using a rabbit recombinant monoclonal EZH2 antibody. EZH2 expression was described and quantified by the percentage of stained tumor cells.Results: Nuclear EZH2 expression occurred in most malignant SGTs (90.00% of ACC and 80.95% of MEC cases), whereas only one benign case of PA (5.88%) showed positive mild staining. Statistical analysis showed a significant difference in the mean of percentage positive cells in SGTs (p<0.001), particularly between benign and malignant SGTs (p<0.001). However, this study observed no significant differences between MEC and ACC (p=0.457).Conclusion: EZH2 expression significantly differed between malignant and benign SGTs, supporting its potential as a diagnostic marker for malignancy in these tumors.","PeriodicalId":15133,"journal":{"name":"Journal of Applied Oral Science","volume":"33 ","pages":"e20250123"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Oral Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/1678-7757-2025-0123","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Enhancer of zeste homolog 2 (EZH2) configures a histone methyl transferase enzyme that mediates the epigenetic silencing of target genes. Its overexpression has been related to tumor proliferation, metastasis, and poor prognoses. However, the study of this protein in salivary gland tumors (SGTs) remains limited.

Objective: This study aimed to investigate EZH2 expression in common intra-oral SGTs, including pleomorphic adenoma (PA), mucoepidermoid carcinoma (MEC), and adenoid cystic carcinoma (ACC).

Methodology: A total of 48 formalin-fixed paraffin-embedded tissue samples were analyzed, including 17 PA, 21 MEC, and 10 ACC cases. Immunohistochemical staining was performed using a rabbit recombinant monoclonal EZH2 antibody. EZH2 expression was described and quantified by the percentage of stained tumor cells.

Results: Nuclear EZH2 expression occurred in most malignant SGTs (90.00% of ACC and 80.95% of MEC cases), whereas only one benign case of PA (5.88%) showed positive mild staining. Statistical analysis showed a significant difference in the mean of percentage positive cells in SGTs (p<0.001), particularly between benign and malignant SGTs (p<0.001). However, this study observed no significant differences between MEC and ACC (p=0.457).

Conclusion: EZH2 expression significantly differed between malignant and benign SGTs, supporting its potential as a diagnostic marker for malignancy in these tumors.

查看原文本刊更多论文

EZH2的表达仅限于恶性唾液腺肿瘤。

背景：zeste同源物2的增强子（Enhancer of zeste homolog 2, EZH2）配置一种组蛋白甲基转移酶，介导靶基因的表观遗传沉默。它的过表达与肿瘤的增殖、转移和预后不良有关。然而，该蛋白在唾液腺肿瘤（sgt）中的研究仍然有限。目的：探讨EZH2在口腔内常见sts(包括多形性腺瘤（PA）、粘液表皮样癌（MEC）和腺样囊性癌（ACC）中的表达。方法：对48例福尔马林固定石蜡包埋组织标本进行分析，其中PA 17例，MEC 21例，ACC 10例。采用兔重组单克隆EZH2抗体进行免疫组化染色。通过染色肿瘤细胞的百分比描述和量化EZH2的表达。结果：大多数恶性sgt（90.00%的ACC和80.95%的MEC）均有核表达EZH2，而良性PA仅1例（5.88%）呈轻度阳性染色。结论：EZH2在恶性和良性sgt中的表达差异显著，支持其作为sgt肿瘤恶性诊断标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Applied Oral Science 医学-牙科与口腔外科

CiteScore

4.80

自引率

3.70%

发文量

审稿时长

4-8 weeks

期刊介绍： The Journal of Applied Oral Science is committed in publishing the scientific and technologic advances achieved by the dental community, according to the quality indicators and peer reviewed material, with the objective of assuring its acceptability at the local, regional, national and international levels. The primary goal of The Journal of Applied Oral Science is to publish the outcomes of original investigations as well as invited case reports and invited reviews in the field of Dentistry and related areas.